Illumina

Illumina is a developer, manufacturer, and marketer of life science tools and integrated systems for large-scale analysis of genetic variation and function. Illumina has developed a line of DNA sequencing technology products that address the scale of experimentation and breadth of functional analysis to advance disease research, drug development, and the development of molecular tests.

Illumina Company Profile 

 

President & CEO: Francis deSouza

CEO photo:

illumina CEO Francis deSouza photo

Website: www.illumina.com

Ticker symbol: ILMN

Headquarters: San Diego, CA

Illumina employees: 5,500+ globally

Revenues: $2.4 Billion USD in 2016

Founded: 1998

Founders: Larry Bock, Anthony Czarnik, David Walt, Mark Chee, John Stuelpnagel

 

Illumina News 

The goal is to generate clinical outcome and economic data that will make the case to payors to cover NIPT for average-risk pregnancies.

Illumina plans to develop clinical-grade products and expects that reimbursement and regulatory trends will further drive growth of its technology in the clinic.

By tapping cloud computing power, ARUP's new "Pipey" system could eventually scale to run 10,000 samples as quickly as it runs one sample.

A jury agreed that Ariosa's noninvasive prenatal test infringed several claims in two patents held by Illumina.

The Seoul-based company also recently raised $1.9 million in series B funding and is targeting between $7 million and $8 million to close the round.

Premaitha had been sued by Illumina for allegedly infringing on five patents related to noninvasive prenatal testing with its Iona test.

Premaitha entered into a secured loan facility agreement with Thermo Fisher, which is secured on the shares of Premaitha's Taiwanese subsidiary, Yourgene Bioscience. 

NGeneBio said this week that its next-generation sequencing panel has been approved as an IVD, the first NGS test to be cleared in Korea.

Over the next three years, the company and its partners will assess the OneRNA platform to diagnose bladder cancer, select treatment, and measure response and recurrence.

The investment bank said that Danaher, Illumina, Qiagen, and Thermo Fisher Scientific were its top picks. 

Pages